SOPHiA GENETICS SA (SOPH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SOPHiA GENETICS SA (SOPH) trades at $5.41 with AI Score 58/100 (Grade B). SOPHiA GENETICS SA operates as a healthcare technology company, providing a cloud-based SaaS platform for data analysis and insights. Market cap: $371.87M, Sector: Healthcare.
Price live · AI analysis from May 6, 2026SOPH stock analysis for 2026: Analysts have set a consensus price target of $7.00 for SOPHiA GENETICS SA, suggesting 29.4% upside from the current price of $5.41. The AI MoonshotScore is 58/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SOPH: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →SOPHiA GENETICS SA (SOPH) Healthcare & Pipeline Overview
SOPHiA GENETICS SA offers the SOPHiA DDM platform, a cloud-based SaaS solution, enabling data analysis and insights for hospitals, labs, and biopharma. With a focus on multimodal data sets and diagnostic modalities, the company aims to improve healthcare outcomes through advanced data analytics, operating in the competitive healthcare technology sector.
What Is the Investment Thesis for SOPH?
SOPHiA GENETICS presents a compelling, albeit high-risk, investment thesis centered on its SOPHiA DDM platform's potential to revolutionize data analysis in healthcare. The company's gross margin of 67.4% indicates strong pricing power and a scalable business model. Growth catalysts include expanding partnerships with biopharma companies and increasing adoption of the platform in clinical settings. However, the company's negative profit margin of -102.2% raises concerns about its path to profitability. Key risks include competition from established players in the healthcare analytics space and the need for continuous innovation to maintain its technological edge. Successful execution of its growth strategy and a clear path to profitability are crucial for realizing the company's long-term potential.
Based on FMP financials and quantitative analysis
SOPH Key Highlights
- SOPHiA DDM Platform: A cloud-based SaaS platform for analyzing multimodal data sets and diagnostic modalities.
- Global Reach: Serving hospitals, laboratories, and biopharma companies worldwide.
- High Gross Margin: 67.4% indicates strong pricing power and a scalable business model.
- Negative Profit Margin: -102.2% raises concerns about the company's path to profitability.
- Beta of 1.04: Suggests the stock's volatility is similar to the market average.
Who Are SOPH's Competitors?
SOPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ILMN Illumina, Inc. | $192.56 | +2.06% | $29.13B | 90 |
| TMO Thermo Fisher Scientific Inc. | $516.82 | -1.26% | $192.06B | 61 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| TXG 10x Genomics, Inc. | $39.63 | +1.59% | $5.03B | 58 |
| WGS GeneDx Holdings Corp. | $68.53 | +1.51% | $2.03B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SOPH's Key Strengths?
- Proprietary SOPHiA DDM platform with advanced data analytics capabilities.
- Global reach and established customer base.
- Strong brand reputation in the healthcare technology sector.
- High gross margin (67.4%) indicates pricing power.
What Are SOPH's Weaknesses?
- Negative profit margin (-102.2%) raises concerns about profitability.
- Reliance on a single platform (SOPHiA DDM).
- Limited diversification of revenue streams.
- High operating expenses.
What Could Drive SOPH Stock Higher?
- Potential new partnerships with pharmaceutical companies to utilize SOPHiA DDM in drug development.
- Increasing adoption of SOPHiA DDM platform by hospitals and laboratories globally.
- Expansion into new therapeutic areas, such as cardiovascular disease and autoimmune disorders.
- Potential regulatory approvals for new AI-powered analytical tools.
What Are the Key Risks for SOPH?
- Financial-distress signal — its Altman Z-Score of -3.50 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger, more established players in the healthcare analytics market.
- Regulatory changes impacting the use of genomic data and data privacy.
- The company's current negative profit margin and the need to achieve profitability.
- Technological obsolescence and the need for continuous innovation to maintain a competitive edge.
- Economic downturns that could reduce healthcare spending and impact customer demand.
What Are the Growth Opportunities for SOPH?
- Expansion into New Therapeutic Areas: SOPHiA GENETICS can expand its platform to support data analysis in new therapeutic areas, such as cardiovascular disease and autoimmune disorders. The market for data-driven solutions in these areas is substantial, with a potential market size of $5 billion by 2030. By developing tailored analytical tools for specific clinical needs, SOPHiA GENETICS can attract new customers and increase its revenue streams. This expansion requires investment in research and development to adapt the SOPHiA DDM platform to the unique data requirements of each therapeutic area.
- Strategic Partnerships with Biopharma Companies: Collaborating with biopharmaceutical companies to integrate the SOPHiA DDM platform into drug discovery and development processes represents a significant growth opportunity. The biopharma industry is increasingly relying on data analytics to accelerate drug development timelines and improve clinical trial outcomes. SOPHiA GENETICS can offer its platform as a valuable tool for analyzing genomic data, identifying drug targets, and personalizing treatment strategies. These partnerships can generate recurring revenue streams and enhance the company's reputation as a leading provider of healthcare data analytics solutions.
- Geographic Expansion into Emerging Markets: Expanding its presence in emerging markets, such as Asia-Pacific and Latin America, offers SOPHiA GENETICS a significant growth opportunity. These regions are experiencing rapid growth in healthcare spending and increasing adoption of digital health technologies. By establishing partnerships with local hospitals and laboratories, SOPHiA GENETICS can gain access to new customer segments and increase its global market share. This expansion requires adapting the SOPHiA DDM platform to local regulatory requirements and language preferences.
- Development of New AI-Powered Analytical Tools: Investing in the development of new AI-powered analytical tools to enhance the capabilities of the SOPHiA DDM platform is crucial for maintaining a competitive edge. The field of artificial intelligence is rapidly evolving, with new algorithms and techniques emerging regularly. SOPHiA GENETICS can leverage these advancements to develop more sophisticated analytical tools that provide deeper insights and improve patient outcomes. This requires ongoing investment in research and development and a commitment to innovation.
- Increased Adoption in Clinical Settings: Driving increased adoption of the SOPHiA DDM platform in clinical settings, such as hospitals and diagnostic laboratories, is essential for long-term growth. By demonstrating the value of the platform in improving patient outcomes and reducing healthcare costs, SOPHiA GENETICS can encourage wider adoption among healthcare providers. This requires targeted marketing efforts, educational programs, and ongoing support to ensure that healthcare professionals can effectively utilize the platform's capabilities.
What Opportunities Does SOPH Have?
- Expansion into new therapeutic areas and geographic markets.
- Strategic partnerships with biopharma companies.
- Development of new AI-powered analytical tools.
- Increased adoption of data-driven medicine in clinical settings.
What Threats Does SOPH Face?
- Competition from established players in the healthcare analytics space.
- Regulatory hurdles and compliance requirements.
- Technological obsolescence and the need for continuous innovation.
- Economic downturns and reduced healthcare spending.
What Are SOPH's Competitive Advantages?
- Proprietary SOPHiA DDM platform with advanced data analytics capabilities.
- Extensive network of hospitals, laboratories, and biopharma partners.
- Strong brand reputation as a leading provider of healthcare data analytics solutions.
- Data network effects: As more users contribute data, the platform's analytical capabilities improve.
What Does SOPH Do?
SOPHiA GENETICS SA, founded in 2011 and headquartered in Saint-Sulpice, Switzerland, is a healthcare technology company focused on data-driven medicine. The company's core offering is the SOPHiA DDM (Data-Driven Medicine) platform, a cloud-based software-as-a-service (SaaS) solution designed to analyze complex multimodal datasets and generate actionable insights. This platform supports a wide range of diagnostic modalities, enabling healthcare professionals and researchers to improve patient outcomes and accelerate drug discovery. SOPHiA GENETICS serves a global clientele, including hospitals, laboratories, and biopharmaceutical companies. The SOPHiA DDM platform facilitates genomic data analysis, enabling precision medicine initiatives and personalized treatment strategies. The company's solutions also extend to areas such as oncology, rare diseases, and infectious diseases, providing tailored analytical tools for specific clinical needs. By leveraging advanced algorithms and machine learning, SOPHiA GENETICS aims to transform raw data into valuable insights, empowering healthcare providers to make more informed decisions and advance medical research.
What Products and Services Does SOPH Offer?
- Offers the SOPHiA DDM platform, a cloud-based SaaS solution.
- Analyzes multimodal data sets and diagnostic modalities.
- Generates insights from complex healthcare data.
- Serves hospitals, laboratories, and biopharma companies worldwide.
- Facilitates genomic data analysis for precision medicine.
- Supports research in oncology, rare diseases, and infectious diseases.
- Provides tailored analytical tools for specific clinical needs.
How Does SOPH Make Money?
- Software-as-a-Service (SaaS) subscription model for the SOPHiA DDM platform.
- Revenue generated from recurring subscription fees.
- Partnerships with biopharma companies for data analysis and drug discovery.
- Global sales and marketing efforts to expand customer base.
What Industry Does SOPH Operate In?
SOPHiA GENETICS operates within the rapidly evolving healthcare information services industry. This sector is characterized by increasing demand for data-driven insights to improve patient outcomes and reduce healthcare costs. The market is competitive, with established players and emerging startups vying for market share. SOPHiA GENETICS differentiates itself through its SOPHiA DDM platform, which offers a comprehensive solution for analyzing multimodal datasets. The industry is expected to continue growing, driven by advancements in genomics, personalized medicine, and the increasing adoption of digital health technologies. SOPHiA GENETICS is positioned to capitalize on these trends, but must navigate regulatory hurdles and maintain its technological edge to remain competitive.
Who Are SOPH's Key Customers?
- Hospitals seeking to improve patient outcomes through data-driven insights.
- Laboratories analyzing genomic data for diagnostic purposes.
- Biopharmaceutical companies using data analytics for drug discovery and development.
- Research institutions conducting medical research.
Company Profile
SOPHiA GENETICS SA operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Rolle, CH. The company is led by CEO Jurgi Camblong. SOPH has traded publicly since 2021.
F-Score 2/9Financial Health
SOPHiA GENETICS SA's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.50 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -51.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.3%, the inverse of the P/E and a quick read on earnings relative to price.
SOPH Valuation & Market Position
With a $371.87M market cap, SOPHiA GENETICS SA sits in the small-cap segment of the market. Relative to its peer group, SOPH's quantitative score of 58/100 is below the peer average of 71/100.
FY2026 estForward Outlook
Wall Street analysts project SOPHiA GENETICS SA revenue of about $93.4M for fiscal 2026, with EPS near $-0.87. The estimate reflects 3 contributing analysts.
Net buyingInsider Activity
Over the past six months, SOPHiA GENETICS SA insiders filed 30 SEC Form 4 transactions — 19 sales and 11 purchases. On net that is roughly 201K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.
SOPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the potential growth of SOPHiA GENETICS.
- Social sentiment has been largely positive, with discussions highlighting the company's innovative approach to data-driven medicine, attracting attention from biotech enthusiasts.
- The ongoing partnerships with leading healthcare institutions reinforce the company's credibility and potential for market expansion in genetic data analysis.
- Recent advancements in their technology have been well-received, signaling a strong alignment with current trends in personalized medicine and data analytics.
Bear Case
- Concerns about the competitive landscape have emerged, with analysts pointing out increasing competition in the genetic analysis sector, which may pressure market share.
- Community sentiment has shown some skepticism regarding the scalability of their business model, as some users question the long-term profitability of their services.
- Recent regulatory hurdles in the biotech space could pose risks to operational timelines and market entry for new products, creating uncertainty.
- Market perception has been affected by broader economic conditions, leading to cautious sentiment among investors about biotech stocks in general.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
SOPH Latest News
-
Is SOPHiA GENETICS SA (SOPH) Among the Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On?
Yahoo! Finance: SOPH News · Jun 23, 2026
-
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
prnewswire.com · Jun 22, 2026
-
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
prnewswire.com · Jun 19, 2026
-
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
seekingalpha.com · Jun 18, 2026
SOPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SOPH.
Price Targets
Consensus target: $7.00
SOPH MoonshotScore
What does this score mean?
The MoonshotScore rates SOPH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Is SOPHiA GENETICS SA (SOPH) Among the Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On?
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
Latest SOPHiA GENETICS SA Analysis
Leadership: Jurgi Camblong
CEO
Jurgi Camblong is the CEO of SOPHiA GENETICS SA. His background includes extensive experience in the healthcare technology sector, with a focus on data-driven medicine and personalized healthcare solutions. He has a strong track record of leading and scaling technology companies. Camblong's expertise spans across various areas, including genomics, bioinformatics, and software development. He is passionate about leveraging data and technology to improve patient outcomes and accelerate medical research. His leadership is instrumental in driving SOPHiA GENETICS' growth and innovation.
Track Record: Under Jurgi Camblong's leadership, SOPHiA GENETICS has expanded its global reach and established partnerships with leading hospitals, laboratories, and biopharma companies. He has overseen the development and commercialization of the SOPHiA DDM platform, a key driver of the company's growth. Camblong has also led successful fundraising efforts, securing capital to support the company's expansion plans. His strategic vision has positioned SOPHiA GENETICS as a leading provider of healthcare data analytics solutions.
SOPH Healthcare Stock FAQ
What does SOPHiA GENETICS S.A. do?
SOPHiA GENETICS SA operates as a healthcare technology company, providing the SOPHiA DDM platform, a cloud-based SaaS solution for analyzing complex multimodal datasets. This platform enables hospitals, laboratories, and biopharmaceutical companies to generate actionable insights from genomic and other healthcare data. By leveraging advanced algorithms and machine learning, SOPHiA GENETICS aims to improve patient outcomes, accelerate drug discovery, and advance precision medicine initiatives globally, positioning itself as a key player in the data-driven healthcare revolution.
What do analysts say about SOPH stock?
Analyst coverage of SOPH is limited, but generally reflects cautious optimism regarding the company's growth potential. Key valuation metrics, such as price-to-sales ratio, are being closely watched. The consensus view acknowledges the potential of the SOPHiA DDM platform and its ability to disrupt the healthcare analytics space. However, concerns remain regarding the company's path to profitability and its ability to compete with larger, more established players. Investors should conduct their own due diligence and consider their risk tolerance before investing.
What are the main risks for SOPH?
SOPHiA GENETICS faces several key risks, including intense competition in the healthcare analytics market, regulatory hurdles related to data privacy and security, and the need for continuous innovation to maintain its technological edge. The company's current negative profit margin also poses a significant risk, as it needs to demonstrate a clear path to profitability to sustain its operations. Furthermore, economic downturns could reduce healthcare spending and impact customer demand, potentially affecting the company's revenue growth. Investors should carefully consider these risks before investing in SOPH.
How does SOPHiA GENETICS S.A. navigate regulatory approval processes?
SOPHiA GENETICS navigates regulatory approval processes by adhering to stringent data privacy and security standards, including GDPR and HIPAA compliance. The company works closely with regulatory bodies to ensure that its SOPHiA DDM platform meets all applicable requirements. SOPHiA GENETICS invests in robust data encryption and access controls to protect sensitive patient information. The company also maintains a dedicated regulatory affairs team to monitor changes in regulations and ensure ongoing compliance. This proactive approach helps SOPHiA GENETICS maintain its reputation as a trusted provider of healthcare data analytics solutions.
What are the key growth opportunities for SOPH in healthcare?
SOPHiA GENETICS has several key growth opportunities in healthcare, including expanding its platform to support data analysis in new therapeutic areas, such as cardiovascular disease and autoimmune disorders. Strategic partnerships with biopharmaceutical companies to integrate the SOPHiA DDM platform into drug discovery and development processes also represent a significant growth opportunity. Additionally, geographic expansion into emerging markets, such as Asia-Pacific and Latin America, offers SOPHiA GENETICS access to new customer segments and increased revenue streams. These opportunities, combined with ongoing innovation in AI-powered analytical tools, position SOPHiA GENETICS for continued growth in the healthcare sector.
What are the key factors to evaluate for SOPH?
SOPHiA GENETICS SA (SOPH) holds an AI score of 58/100 (moderate). Analysts target $7.00 (+29%). Not financial advice.
How frequently does SOPH data refresh on this page?
SOPH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SOPH's recent stock price performance?
SOPHiA GENETICS SA (SOPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SOPHiA DDM platform with advanced data analytics capabilities. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst opinions may vary and are subject to change.
- This analysis is for informational purposes only and does not constitute investment advice.